{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-076728","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.987367+00:00","generated_at":"2026-05-31T05:56:52.908240+00:00","sec_items":["3.03","5.03","5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity Therapeutics files 1-for-30 reverse stock split, reduces authorized shares to 250M","bullets":["Stockholders approved 1-for-30 reverse split at Sept 3 annual meeting; effective Sept 11, 2024.","Authorized common shares reduced from 750M to 250M via Sixth Certificate of Amendment.","Board also amended 2021 Equity Plan to increase shares reserved from ~2.2M to ~10.6M (pre-split).","Directors Gerald W. McLaughlin and Laura E. Benjamin re-elected to Class II.","Trading symbol ALLR unchanged; no fractional shares, rounding up."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-076728","json":"https://secwatch.observer/filing/0001213900-24-076728.json","markdown":"https://secwatch.observer/filing/0001213900-24-076728.md","text":"https://secwatch.observer/filing/0001213900-24-076728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024076728/0001213900-24-076728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024076728/ea0213202-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:56:52.908240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}